A new study suggests that two inherited cardiomyopathies—dilated cardiomyopathy (DCM) and left ventricular non-compaction (LVNC)—can diverge dramatically from an almost identical genetic change. The work, led largely by researchers from Würzburg, Heidelberg, and Göttingen, targets the RBM20 gene, whose mutations are known to drive rare heart failure syndromes.
Clinically, DCM features markedly enlarged heart chambers and impaired pumping, whereas LVNC is defined by spongy, honeycomb-like myocardium. Until now, patients carrying RBM20 variants have largely received standard heart-failure care, despite the possibility that this molecular subgroup might respond to more tailored therapies.
The researchers examined two families with RBM20 mutations that differ by just a single protein “letter” at the same critical site. In the DCM family, an arginine is replaced by tryptophan; in the LVNC family, the same arginine is replaced by leucine. The subtlety of the difference makes the contrasting phenotypes especially striking.
To explain how one residue shift could remodel cardiac physiology, the team probed calcium handling in patient-derived material. They found distinct calcium-system failures: LVNC models showed heightened calcium-cycle activity and an energetically costly calcium regime, while DCM models behaved as if internal calcium stores leak, disrupting rhythmic contraction–relaxation coupling.
The study used pluripotent stem cell technology to recreate disease-relevant heart muscle in vitro. Induced pluripotent stem cells (iPSCs) were differentiated into beating cardiomyocytes, and the researchers further generated organoid-like spherical models as well as engineered micro–heart muscle tissues to better mimic tissue-scale behavior.
To establish causality rather than correlation, CRISPR/Cas9 was applied as “gene scissors” to correct defective RBM20 in diseased cells. The team then reintroduced the DCM mutation into repaired LVNC backgrounds, demonstrating that the specific RBM20 change at that single site is sufficient to generate the divergent calcium phenotypes.
From these mechanistic insights, the researchers mapped potential “molecular players” that may guide precision drug targeting. Among the candidates, verapamil—an established calcium-effect blocker used clinically for arrhythmias—showed partial improvement of contractile performance in laboratory experiments.
The authors emphasize that translating these findings to patients will require extensive preclinical validation. Still, the results outline a roadmap for individualized therapies, where genetic diagnosis could inform which calcium-related pathway to modulate in RBM20-associated disease.
Subject of Research: Cells
Article Title: RBM20 variants disrupt Ca2+ handling and metabolism in dilated and non-compaction cardiomyopathy stem cell models
News Publication Date: 14-Jul-2026
Web References: http://dx.doi.org/10.1038/s41392-026-02838-7
References: 10.1038/s41392-026-02838-7
Image Credits: Katrin Streckfuß-Bömeke / University of Würzburg
Keywords: cardiomyopathy, RBM20, calcium homeostasis, LVNC, DCM, iPSCs, CRISPR/Cas9, stem cell models, verapamil
